Blood cancers like multiple myeloma have long been considered incurable. But in the last decade, the development of precision immunotherapy treatments has offered patients months or even years of extended life. One such treatment, known as CAR-T cell therapy, turns immune system T cells into killers of cancer cells. They have been so transformative that earlier this year, doctors wrote that CAR-T had cured a man who in 2010 was the second patient to receive the treatment.
CAR-T therapies are now approved to treat a variety of blood cell cancers, including myeloma, lymphoma and some types of leukemia. But drugmakers have had difficulty keeping up with the demand for CAR-T cells, creating a wrenching dilemma for doctors who must decide which blood cancer patients need the therapy immediately and which can afford to wait.
And as promising as CAR-T has been for blood cancers, it is far from a panacea. The treatment does not work for all patients. Many others eventually suffer a relapse of their cancers. And CAR-T has so far produced uninspiring results for solid tumor cancers like those of the lung and kidney, although researchers are making progress here through additional engineering and technologies to enhance the performance of CAR-T cells.
The articles in this e-book track the changing prognosis for blood cancer patients and the future potential of this game-changing approach to treatment.
Publication date: December 2022
Print length: 76 pages
File size: 2.6 MB
File format: PDF
Enter the information below to begin your free e-book download
About the sponsor
About the sponsor
[email protected] aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.